- Previous Close
11.36 - Open
10.79 - Bid 10.10 x 100
- Ask 10.58 x 100
- Day's Range
9.80 - 10.98 - 52 Week Range
8.85 - 41.87 - Volume
183,120 - Avg. Volume
89,570 - Market Cap (intraday)
294.305M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-4.09 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
37.33
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA) for the treatment of autoimmune diseases, currently under Phase 2b clinical development for generalized myasthenia gravis, systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It develops Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases such as relapsed/refractory multiple myeloma. Cartesian Therapeutics, Inc. is headquartered in Frederick, Maryland.
www.cartesiantherapeutics.comRecent News: RNAC
View MorePerformance Overview: RNAC
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RNAC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RNAC
View MoreValuation Measures
Market Cap
294.30M
Enterprise Value
95.68M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.07
Price/Book (mrq)
--
Enterprise Value/Revenue
2.46
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-198.97%
Return on Assets (ttm)
-6.00%
Return on Equity (ttm)
--
Revenue (ttm)
38.91M
Net Income Avi to Common (ttm)
-77.42M
Diluted EPS (ttm)
-4.09
Balance Sheet and Cash Flow
Total Cash (mrq)
212.61M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-59.67M